AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study
AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug conjugate Enhertu (trastuzumab deruxtecan) in a subset of breast cancer patients. The phase 3 DESTINY-Breast06 has been comparing …